As IPF and SSc fibroblasts have high levels of active/steady-state TGFβ1 expression, our findings suggest that in vivo IGF-II is likely inducing TGFβ2 and TGFβ3, thus contributing to and perpetuating the fibrotic phenotype. The gene discussed is TGFB1; the disease is systemic sclerosis.